GlassScriptPhysician profile
Alice C Furman
NPI 1861411365
$5,679.01
in general payments reported to CMS, 2019-2025
35 companies · $728 in 2025
The $728 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $502 · 2021: $443 · 2022: $853 · 2023: $807 · 2024: $1,024 · 2025: $728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,558.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,536.07 | 2019-2025 | |
| Glaxosmithkline, LLC. | $490.29 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $363.38 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $336.45 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $324.14 | 2019-2025 | Evenity |
| Lilly USA, LLC | $290.14 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $249.87 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.29 | 2019-2025 | Xifaxan |
| Pfizer INC. | $241.92 | 2021-2025 | |
| Gilead Sciences, INC. | $227.06 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $199.08 | 2022-2023 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.62 | 2019-2025 | Ofev |
| Exact Sciences Corporation | $142.66 | 2023-2025 | Cologuard Collection Kit |
| Bausch Health US, LLC | $116.76 | 2021-2025 | Wellbutrin, Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $93.15 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $81.25 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $68.85 | 2024-2025 | |
| Allergan, INC. | $63.21 | 2019-2020 | |
| Almatica Pharma LLC | $61.60 | 2024-2025 | Loreev Xr |
| Amarin Pharma, INC. | $55.24 | 2019-2020 | |
| Philips North America LLC | $48.10 | 2024 | (Ck7) Extended Holter |
| Sanofi Pasteur INC. | $40.84 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $29.01 | 2022 | |
| Dynavax Technologies Corporation | $24.71 | 2019 | |
| Endo Pharmaceuticals INC. | $23.78 | 2019 | |
| Bardy Diagnostics, INC. | $22.50 | 2022 | |
| Ibsa Pharma INC. | $21.58 | 2024 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $20.65 | 2019 | |
| Bavarian Nordic A/S | $18.89 | 2025 | Vivotif |
| Paratek Pharmaceuticals, INC. | $17.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.64 | 2022 | |
| Idorsia Pharmaceuticals US INC | $16.48 | 2023 | Quviviq |
| Intra-Sana Laboratories | $15.86 | 2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Genentech USA, INC. | $13.94 | 2020 | |
| Astellas Pharma US INC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Furman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.